跳至主要内容
临床试验/NCT07148752
NCT07148752尚未招募不适用

Evaluation of Amoebicidal Efficacy of Resveratrol and Resveratrol Loaded Nanoparticles on Acanthamoeba Keratitis Isolates

Assiut University0 个研究点目标入组 50 人开始时间: 2025年10月15日最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
50
主要终点
Invitro evaluation of amoebicidal efficacy of resveratrol and resveratrol loaded nanoparticles against the isolated Acanthamoeba pathogenic strains from corneal ulcers patients in comparison to the reference drug through experimental study.

研究概览

简要总结

Acanthamoeba is a free-living amoeba responsible for severe human infections. There are at least twenty-two different genotypes of Acanthamoeba (T1-T22). T4 is the most common virulent genotype, mainly Acanthamoeba castellani and Acanthamoeba polyphaga.

Proper treatment still represents a challenge for healthcare professionals.So, we need novel therapeutic strategies, including newer drugs and/or drug delivery systems that can overcome the developing drug resistance as well as have minimal toxicity to human cells.

There is a new approach in the treatment of parasitic disease by using nanotechnology and natural compounds as plant extracts.

The current study aims to evaluate the therapeutic potential of resveratrol, both in its free form and when loaded on nanoparticles, against clinically isolated Acanthamoeba strains obtained from patients with persistent AK or corneal ulcers.

详细描述

: 1-Specimen collection using: A- Corneal swabs. B- Corneal scraping and superficial keratectomy.

C- Contact lenses and contact lens solutions. 2-Culture: The collected samples will be cultivated on non-nutrient agar (NNA) plates seeded with heat-killed Escherichia coli.

3-Cultivation and maintenance of Acanthamoeba isolates in axenic culture: PYG media will be used in order to obtain a significant number of parasites with a minimum presence of bacteria.

4-Molecular analysis:Positive samples by culture will be subjected to conventional PCR technique for molecular characterization of Acanthamoeba at the genus level using genus-specific primers: Forward primer JDP1: F5'-GGC CCAGATCGTTTACCGTGAA-3'

- Reverse primer JDP2:R5' TCTCACAAGCTGCTAGGG AGTCA-3' 5- Sequencing and phylogenetic study: The amplified DNA will be purified, sequencing ASA.S1 region of the 18s rRNA gene will be performed. Following genotyping, the Basic Local Alignment Search Tool (BLAST) of the US National Center for Biotechnology Information (NCBI) will be used to identify similar Acanthamoeba sequences.

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients presented with keratitis to the outpatient clinic.
  • Patients presented with corneal ulcers to the outpatient clinic.

排除标准

  • Patients presented with corneal ulcers caused by pathogens rather than Acanthamoeba (bacterial, viral or fungal).
  • Patients presented with other eye conditions that act as confounding variable as corneal perforation, severe dry eye, glaucoma, scleritis and active uveitis.
  • Patients with history of previous ocular surgery or corneal transplant.

结局指标

主要结局

Invitro evaluation of amoebicidal efficacy of resveratrol and resveratrol loaded nanoparticles against the isolated Acanthamoeba pathogenic strains from corneal ulcers patients in comparison to the reference drug through experimental study.

时间窗: 2025-2028

In-vitro experimental study: A-Drug susceptibility testing :The Acanthamoeba isolates will be tested for their susceptibility to various drug groups serial dilutions. The number of cysts/trophozoites will be counted using a hemocytometer. B-Viability measurements: Using trypan blue viability stain. C-Scanning electron microscopy (SEM). D-Host cells cytotoxicity evaluation using MTT assay on HeLa cell line: -Percentage of cell cytotoxicity will be calculated, and the acceptable limit of cytotoxicity will be taken as the viability cutoff of 60%; thus, a cytotoxicity of \>40% is considered unacceptable.

Invivo evaluation of amoebicidal efficacy of resveratrol and resveratrol loaded nanoparticles against the isolated Acanthamoeba pathogenic strains from corneal ulcers patients in comparison to the reference drug through experimental study.

时间窗: 2025-2028

II- In-vivo experimental study: * The sample size is calculated to be 35 tested animals (5 in each group). * Procedure: Induction of keratitis and confirmation of the infection Application of the tested drug (7 groups as previously discussed). -Evaluation of treatment by: Clinical evaluation (examination and scoring of the tested animal's eyes). Histopathological evaluation of corneal tissue: Parasitological evaluation.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Reham Hany Mohammed

assistant lecturere

Assiut University

相似试验